ABIONYX Pharma SA (FR:ABNX)
:ABNX
ABNX Stock Chart & Stats
€3.70
>-€0.01(-0.63%)
At close: 4:00 PM EST
€3.70
>-€0.01(-0.63%)
Day’s Range― - ―
52-Week Range€1.09 - €5.29
Previous CloseN/A
Volume9.43K
Average Volume (3M)284.77K
Market Cap
€130.17M
Enterprise Value€130.56M
Total Cash (Recent Filing)€3.52M
Total Debt (Recent Filing)€3.81M
Price to Earnings (P/E)―
Beta-0.62
Next Earnings
Sep 24, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.09
Shares Outstanding35,511,654
10 Day Avg. Volume172,880
30 Day Avg. Volume284,772
Financial Highlights & Ratios
PEG Ratio-1.05
Price to Book (P/B)31.58
Price to Sales (P/S)33.12
P/FCF Ratio-42.38
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.47
Revenue Forecast (FY)€4.66M
Bulls Say, Bears Say
Bulls Say
Specialized R&D PlatformABIONYX’s focused apoA‑I therapeutic platform represents a durable scientific specialization across inflammatory, infectious and severe disease indications. A clear mechanism and platform focus support multi‑indication development, potential licensing opportunities, and long‑term value if clinical validation is achieved.
Positive Equity BufferMaintaining positive equity (~€4.26m in 2025) provides a solvency buffer that supports continued operations and clinical activity. While reduced versus prior years, this balance‑sheet headroom helps sustain development timelines and gives management room to pursue partnerships or staged financing over the medium term.
Improving Cash Burn And Revenue ProgressOperating cash outflows have moderated relative to 2024 and reported revenues are meaningfully higher than the near‑zero base in earlier periods. This indicates initial operational progress and partially reduced financing pressure, which can lower dilution risk and support incremental de‑risking of clinical programs over months.
Bears Say
Persistent Cash BurnConsistent negative operating (~‑€2.93m) and free cash flow (~‑€3.18m) indicate ongoing cash consumption tied to R&D and operations. Persistently negative cash generation creates structural financing needs, increasing reliance on external capital or partnerships and raising the probability of dilution or constrained program pacing over the medium term.
Deep Negative MarginsA sharp decline in gross margin (~9%) and an extremely negative EBIT margin (~‑154%) show the business is far from profitable. Such structural losses imply the current cost and revenue profile cannot sustain operations without significant margin improvement, successful high‑value milestones, or a shift in revenue mix.
Rising Leverage And Eroding EquityLeverage has risen materially (debt/equity ~0.89) while equity has eroded, reducing financial flexibility. Higher indebtedness increases refinancing and interest risks, which can make funding costly and constrain the company’s ability to self‑finance clinical programs or negotiate favorable partnership terms over the coming months.
ABNX FAQ
What was ABIONYX Pharma SA’s price range in the past 12 months?
ABIONYX Pharma SA lowest stock price was €1.09 and its highest was €5.29 in the past 12 months.
What is ABIONYX Pharma SA’s market cap?
ABIONYX Pharma SA’s market cap is €130.17M.
When is ABIONYX Pharma SA’s upcoming earnings report date?
ABIONYX Pharma SA’s upcoming earnings report date is Sep 24, 2026 which is in 171 days.
How were ABIONYX Pharma SA’s earnings last quarter?
ABIONYX Pharma SA released its earnings results on Mar 12, 2026. The company reported -€0.092 earnings per share for the quarter, missing the consensus estimate of N/A by -€0.092.
Is ABIONYX Pharma SA overvalued?
According to Wall Street analysts ABIONYX Pharma SA’s price is currently Overvalued.
Does ABIONYX Pharma SA pay dividends?
ABIONYX Pharma SA does not currently pay dividends.
What is ABIONYX Pharma SA’s EPS estimate?
ABIONYX Pharma SA’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does ABIONYX Pharma SA have?
ABIONYX Pharma SA has 35,511,654 shares outstanding.
What happened to ABIONYX Pharma SA’s price movement after its last earnings report?
ABIONYX Pharma SA reported an EPS of -€0.092 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 0.448%.
Which hedge fund is a major shareholder of ABIONYX Pharma SA?
Currently, no hedge funds are holding shares in FR:ABNX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
ABIONYX Pharma SA
ABIONYX Pharma SA, a biotech company, discovers and develops therapies for the treatment of renal and ophthalmological diseases. The company is developing CER-001, a negatively-charged lipoprotein particle which contains human recombinant apoA-I, the natural high density lipoprotein (HDL) protein, and sphingomyelin and dipalmitoylphosphatidylglycerol natural phospholipids designed to mimicks the structural and functional biological properties of pre-beta HDL for the treatment of post-acute coronary syndrome patients and familial primary hypoalphalipoproteinemia patients; CER-002, a peroxisome proliferator-activated receptor delta specific agonist for the treatment of cardiovascular and metabolic diseases; and CER-209, a drug candidate for the treatment of metabolic diseases in the liver, as well as atherosclerois and non-alcoholic steato-hepatitis. It has a strategic partnership with GTP Biologics and VBI Therapeutics Group for the bioproduction of the bio-HDL in France. The company was formerly known as Cerenis Therapeutics Holding SA and changed its name to ABIONYX Pharma SA in August 2019. ABIONYX Pharma SA was founded in 2005 and is based in Balma, France.